Skip to main content

Peripheral Neuropathy and cannabis in New Jersey

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Up to 3 oz per 30-day s…
POSSESSION
$0/yr
STATE FEE
7–21 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

New Jersey statute and program

The New Jersey Medicinal Cannabis Program is the operating authority for New Jersey patient certification. The authoritative legal text is: N.J.S.A. 24:6I: Compassionate Use Medical Cannabis Act / CREAMMA. The program portal is at New Jersey Medicinal Cannabis Program.

What the evidence says about cannabis and Peripheral Neuropathy

Peripheral neuropathy is damage to or dysfunction of the peripheral nervous system (nerves outside the brain and spinal cord). Common causes include diabetes mellitus, chemotherapy, HIV infection, alcohol use, autoimmune disease, vitamin deficiency, infection, trauma, and inherited disorders. Symptoms typically include burning or shooting pain, tingling, numbness, weakness, and loss of coordination, most often in a stocking-glove distribution affecting feet first and then hands.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Peripheral Neuropathy page.

How to qualify in New Jersey

The New Jersey Medicinal Cannabis Program requires the following registration steps for a Peripheral Neuropathy patient (or any qualifying diagnosis):

  1. Get a written certification from a New Jersey healthcare practitioner. Any New Jersey-licensed physician, advanced practice nurse, or physician assistant authorized to prescribe Schedule II controlled substances may certify a patient for the Medicinal Cannabis Program — no separate program registration is required for the practitioner since the 2019 Jake Honig Compassionate Use Medical Cannabis Act expanded the prescribing pool. The practitioner determines whether medical cannabis may benefit the patient under N.J.S.A. 24:6I.
  2. Receive the patient reference number from your practitioner. The certifying practitioner uses the NJ Cannabis Regulatory Commission (CRC) provider portal to issue the patient a reference number that the patient then uses to complete the online patient registration through the CRC patient portal. Patients upload a NJ driver license or state ID and a passport-style photograph.
  3. Complete the online patient registration (no state fee since 2022). The state patient registration fee was eliminated under 2022 CRC reforms — there is no annual state registration fee for patients or designated caregivers. Patients only pay the practitioner certification fee plus standard product costs at dispensaries.
  4. Purchase from a New Jersey Alternative Treatment Center. Once approved, patients receive a digital and physical medicinal cannabis card and may purchase up to a 3-ounce 30-day supply from any New Jersey Alternative Treatment Center (ATC). Adult-use retail also operates statewide for adults 21+, but medical patients retain lower taxation, prioritized inventory access, higher purchase limits for terminal patients, and statutory employment and child-custody protections.
State registration fee
$0
Physician visit (typical)
$200–$400
Certification to card
7–21 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full New Jersey registration steps, fees, and reciprocity rules, see the New Jersey cannabis-laws page.

ICD-10 code

A certifying physician documenting Peripheral Neuropathy for the New Jersey medical cannabis program will typically record ICD-10 G62.9 or SNOMED-CT 42658009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does New Jersey list Peripheral Neuropathy as a qualifying condition for medical cannabis?

No. New Jersey's qualifying-condition list does not currently include Peripheral Neuropathy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Peripheral Neuropathy in New Jersey have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. New Jersey program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a New Jersey medical marijuana card for Peripheral Neuropathy?

Because New Jersey does not currently list Peripheral Neuropathy as a qualifying condition, a card for Peripheral Neuropathy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in New Jersey who is registered with New Jersey Medicinal Cannabis Program and willing to evaluate Peripheral Neuropathy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. New Jersey does not honor out-of-state cards, so the certification process has to originate inside the state. The state minimum patient age is 18; minors generally require a parent or legal guardian to act as caregiver. The authoritative source for the current process is the New Jersey Medicinal Cannabis Program site at https://www.nj.gov/cannabis/; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Peripheral Neuropathy?

For Peripheral Neuropathy, evidence is described as moderate (supportive controlled studies exist but the picture is mixed). The mmjnow condition page for Peripheral Neuropathy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Peripheral Neuropathy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Peripheral Neuropathy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Peripheral Neuropathy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. N.J.S.A. 24:6I: Compassionate Use Medical Cannabis Act / CREAMMAaccessed May 15, 2026
  2. New Jersey Cannabis Regulatory Commissionaccessed May 15, 2026
  3. NORML: New Jersey Lawsaccessed May 15, 2026
  4. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 16, 2026

    “Substantial evidence that cannabis is an effective treatment for chronic pain in adults.”

  5. NIH NINDS: Peripheral Neuropathyaccessed May 16, 2026